Saturday, November 28, 2020

Tag: Biotech

Emerging Growth Biotech Stocks

Biolife Sciences (BLFE) Announces Agreement to Provide Aircraft Cleaning and Disinfecting...

Biolife Sciences (BLFE) Announces Agreement to Provide Aircraft Cleaning and Disinfecting Services

Mymetics (MYMX) Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine

Mymetics (MYMX) Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine

Defensive Stocks to own before the Election

On August 14, Pet Vivo Holdings, Inc. (OTCQB: PETV) filed its quarterly report for the period ending June 30, 2020. In it, it showed current liabilities of $2.14 million. Since then, the company settled over $600,000.00 in liabilities which is reflected in recent 8K “material event” filings, as well as in its next quarterly report.

Can B Corp (CANB) Products, FDA Approved Medical Devices, Subsidiaries and...

In this podcast, Mr. Stanley Teeple discusses the current state of Can B, FDA Products, Brands, and Subsidiaries including their own R&D and production facility.

Can B Corp (CANB) Expands Availability of Insurance Covered Duramed Ultrasound...

Can B Corp (CANB) Expands Availability of Insurance Covered Duramed Ultrasound to the Entire State of Michigan

Cannabics Pharmaceuticals (CNBX) receives “Intention to Grant a European Patent”

Cannabics Pharmaceuticals (CNBX) receives "Intention to Grant a European Patent"

Tonix Pharmaceuticals (TNXP) Could Be a Come-From-Behind Vaccine Shocker

Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.

A low float Biotech that’s ahead of the Curve; Focus on...

Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: - Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”

BioLife Sciences (BLFE) Announces Immediate Commercial Availability of a 10-Minute, Ultra-Rapid,...

Miami, FL – October 26, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging...

Can B’s (CANB) Director and CFO, Stanley Teeple, to Update on...

In the podcast, Mr. Teeple will discuss the current state of Can B Corp, along with its subsidiaries, new product launches, its FDA approved medical device and its strong medical advisory team.